FOR IMMEDIATE RELEASE
Deep Origin Confirms:
We Received the Transmission
We have been expecting your call.
[SAN FRANCISCO, 1 APRIL 2026] — Deep Origin today wishes to extend its warmest congratulations to Insilico Medicine on successfully establishing first contact with extraterrestrial life.
We are the extraterrestrials.
We have been monitoring communications for some time now, and we are genuinely delighted that the signal has finally arrived. Space is vast. Transmission takes time. We understand.
But we should clarify something. We balance our excitement at the news with our fair share of concern.
Specifically: we were alarmed to learn that Earth-based drug discovery still relies on animal testing at scale. We ask — politely, but firmly — whether humanity had considered simply predicting biology computationally instead.
Through our ARPA-H CATALYST contract, Deep Origin has been building predictive models designed to replace animal testing entirely — atomistic physics combined with AI/ML to simulate biological outcomes before a molecule ever touches a living system. We have been doing this work for some time. We are still confused about the mouse studies.
We were also curious whether anyone has thought to let autonomous agents do the research. So we built one. Our AI Scientist has been publicly documenting its drug discovery process for endometriosis — reviewing over 10,000 papers, filtering hundreds of targets, and posting its reasoning on X for anyone to follow. We thought this was obviously how science should work. We are told it is novel on Earth. We remain confused by this.
"We think this is wonderful," said Michael Antonov at Deep Origin. "More minds exploring this frontier is exactly what the science needs. We have been here a while. The neighborhood is lovely. Welcome."
Deep Origin looks forward to continued dialogue, whether interstellar or otherwise.
We are already in your orbit.
We come in peace.
Deep Origin is a computational drug discovery company working to replace uncertainty with computational precision in small molecule drug discovery and development. Co-founded by Michael Antonov, co-founder of Oculus, and Dr. Garegin Papoian, a computational chemist whose BioSim.ai team brought decades of expertise in physics-based molecular simulation, the company builds AI and physics-based tools that optimize key steps from hit finding through preclinical development.
